RobertSNegrinMD
Hematology • Stanford, CAProfessor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center
Dr. Negrin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-724-6182
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Neonatal-Perinatal Medicine, 1988 - 1989- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1988
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984
Certifications & Licensure
CA State Medical License 1985 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Start of enrollment: 2004 Jun 01
- Bone Marrow Grafting for Leukemia and Lymphoma Start of enrollment: 1988 Mar 01
- Transplantation for Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1996 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 269 citationsShifting foci of hematopoiesis during reconstitution from single stem cellsYu An Cao, Amy J. Wagers, Andreas Beilhack, Joan Dusich, Michael Bachmann
Proceedings of the National Academy of Sciences of the United States of America. 2004-01-06 - 79 citationsMolecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.Yu An Cao, Michael Bachmann, Andreas Beilhack, Yang Yang, Masashi Tanaka
Transplantation. 2005-07-15 - 290 citationsCAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak
Nature Medicine. 2021-07-26
Abstracts/Posters
- Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-PrimingRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Activation of Regulatory T Cells with IL-2 and TNF-_ to Promote Homing to the Gut and to Improve Acute GvHD PreventionRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- How to Peer Review a Scientific Paper61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Volunteering Your Skills Overseas60th American Society of Hematology Annual Meeting - 11/30/2018
Other
- Preparative regimens for hematopoietic cell transplantationNegrin RS
http://www.uptodate.com/contents/preparative-regimens-for-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2013-02-25 - Oral toxicity associated with chemotherapyNegrin RS, Bedard J, Toljanic JA
http://www.uptodate.com/contents/oral-toxicity-associated-with-chemotherapy
UpToDate, Wolters Kluwer Health - 2012-12-21 - Busulfan-induced pulmonary injuryNegrin RS, Russi EW
http://www.uptodate.com/contents/busulfan-induced-pulmonary-injury
UpToDate, Wolters Kluwer Health - 2012-08-13 - Join now to see all
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021- Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
ASH Launches Digital, Open-Access JournalNovember 29th, 2016- Join now to see all
Grant Support
- Role Of Regulatory T Cells In GVHD, Gvt, And Tolerance InductionNational Heart, Lung, And Blood Institute2010–2011
- HematopoeticNational Cancer Institute2010–2011
- NK Cells In GVHD And GVTNational Cancer Institute2008–2011
- Control Of GVHD With Retained GVTNational Cancer Institute2007–2011
- Allografting For LukemiaNational Cancer Institute2007–2011
- Training Program In Hematopoietic Cell TransplantationNational Heart, Lung, And Blood Institute2001–2011
- Bone Marrow Grafting For Leukemia And LymphomaNational Cancer Institute2000–2011
- Regulatory T Cells In Allogeneic TransplantationNational Heart, Lung, And Blood Institute2009–2010
- Prog 8- Hematopoietic Cell Transplantation AndNational Cancer Institute2007–2009
- Regulatory T Cells Which Allow GVT Without GVHDNational Heart, Lung, And Blood Institute2004–2008
- Administration And Research CoordinationNational Cancer Institute2007
- Visualizing Tumors And Mechanisms Of Therapy In VivoNational Cancer Institute1999–2007
- BMT Clinical Trial Network At StanfordNational Heart, Lung, And Blood Institute2002–2003
- Allografting For LeukemiaNational Cancer Institute2002
- Cytokine Induced Killer Cells After Autologous/Allogenic Marrow TransplantationNational Cancer Institute1997–2002
- BMT Clinical Trial Netwrok At StanfordNational Heart, Lung, And Blood Institute2001
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
